When treat­ing Alzheimer’s, ear­li­er is bet­ter, ac­cord­ing to analy­sis of Lil­ly and Ei­sai tri­als

The drug­mak­ers be­hind the new class of Alzheimer’s treat­ments are co­a­lesc­ing around a com­mon nar­ra­tive: When it comes to slow­ing the dis­ease, the ear­li­er a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA